Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 8

Ceruloplasmin and iron in Alzheimer’s disease and Parkinson’s disease: a synopsis of recent studies

Authors Kristinsson J, Snaedal J, Tórsdóttir G, Jóhannesson T

Published Date November 2012 Volume 2012:8 Pages 515—521

DOI http://dx.doi.org/10.2147/NDT.S34729

Received 7 June 2012, Accepted 20 July 2012, Published 2 November 2012

Jakob Kristinsson,1 Jón Snaedal,2 Gudlaug Tórsdóttir,1,2 Torkell Jóhannesson1

1Department of Pharmacology and Toxicology, University of Iceland, Reykjavik, Iceland; 2Department of Geriatrics, Landspitali University Hospital, Reykjavik, Iceland

Abstract: Ceruloplasmin (Cp) concentration and oxidative activity in serum are lowered in Parkinson’s disease (PD). In most PD patients, iron increases in the substantia nigra in the midbrain. In PD, the low Cp concentration and activity in serum and the high iron amounts in the substantia nigra appears to be correlated. An hereditary background is common in PD and variations in the Cp gene that have been found in PD are associated with high iron levels in the substantia nigra. Variations in Cp synthesis and in the incorporation of copper into the Cp molecule are essential features of PD. In Alzheimer’s disease (AD), the Cp activity in serum is lowered but not the concentration, except in the advanced stages of the disease. Generally, iron is not increased in the AD brain. In the AD brain, iron accumulates in neuritic plaques and in neurofibrillary tangles. There is also increased risk of iron-mediated tissue damage, which may possibly be counteracted by Cp. At the same time, the AD brain is short in copper, which presumably results in the deficient activity of many copper enzymes in the brain, in addition to Cp. Lowered Cp activity in serum most likely stems from lessened incorporation of copper in the Cp molecule and similar incorporation defects might also apply to other copper enzymes in AD.

Keywords: ceruloplasmin, iron, copper, Alzheimer´s disease, Parkinson´s disease

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Clinical outcome of incidentally discovered small renal cell carcinoma after delayed surgery

Sugimoto K, Shimizu N, Oki T, Nose K, Nishioka T, Adomi S, Ohzeki T, Esa A, Uemura H

Cancer Management and Research 2013, 5:85-89

Published Date: 24 May 2013

Estimating adolescent sleep patterns: parent reports versus adolescent self-report surveys, sleep diaries, and actigraphy

Short MA, Gradisar M, Lack LC, Wright HR, Chatburn A

Nature and Science of Sleep 2013, 5:23-26

Published Date: 12 February 2013

Can headache impair intellectual abilities in children? An observational study

Esposito M, Pascotto A, Gallai B, Parisi L, Roccella M, Marotta R, Lavano SM, Gritti A, Mazzotta G, Carotenuto M

Neuropsychiatric Disease and Treatment 2012, 8:509-513

Published Date: 1 November 2012

Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?

Mezei Z, Bereczki D, Racz L, Csiba L, Csepany T

Neuropsychiatric Disease and Treatment 2012, 8:465-473

Published Date: 23 October 2012

Parkinson’s disease patients’ subjective descriptions of characteristics of chronic pain, sleeping patterns and health-related quality of life

Skogar Ö, Fall P-A, Hallgren G, Bringer B, Carlsson M, Lennartsson U, Sandbjörk H, Törnhage C-J, Lökk J

Neuropsychiatric Disease and Treatment 2012, 8:435-442

Published Date: 12 October 2012

Studying the effect of particle size and coating type on the blood kinetics of superparamagnetic iron oxide nanoparticles

Roohi F, Lohrke J, Ide A, Schuetz G, Dassler K

International Journal of Nanomedicine 2012, 7:4447-4458

Published Date: 10 August 2012

Preparation, characterization, and cytotoxicity of CPT/Fe2O3-embedded PLGA ultrafine composite fibers: a synergistic approach to develop promising anticancer material

Amna T, Hassan MS, Nam KT, Bing YY, Barakat NAM , Khil MS, Kim HY

International Journal of Nanomedicine 2012, 7:1659-1670

Published Date: 27 March 2012

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Apoptotic and chemotherapeutic properties of iron(III)-salophene in an ovarian cancer animal model

Thilo S Lange, Carolyn McCourt, Rakesh K Singh, Kyu Kwang Kim, Ajay P Singh, et al

Drug Design, Development and Therapy 2009, 3:17-26

Published Date: 17 December 2008